Disposition and metabolism of cabotegravir: A comparison of biotransformation and excretion between different species and routes of administration in humans

Xenobiotica

Volumn 46, Issue 2, 2016, Pages 147-162

  Bowers, Gary David ^a   Culp, Amanda ^a   Reese, Melinda J ^a   Tabolt, Glenn ^a   Moss, Lee ^a   Piscitelli, Stephen ^a   Huynh, Phuong ^a   Wagner, David ^a   Ford, Susan L ^a   Gould, Elizabeth P ^a   Pan, Rennan ^a   Lou, Yu ^a   Margolis, David A ^a   Spreen, William R ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

HIV 1; integrase inhibitor; long acting injectable; nanosuspension

Indexed keywords

CABOTEGRAVIR; CABOTEGRAVIR C 14; CABOTEGRAVIR GLUCURONIDE C 14; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A9; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; GLUCURONIC ACID; GLUCURONOSYLTRANSFERASE; INTEGRASE INHIBITOR; PYRIDONE DERIVATIVE; UDP-GLUCURONOSYLTRANSFERASE 1A9; UGT1A1 ENZYME;

ADULT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DEATH; DIARRHEA; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG URINE LEVEL; ELIMINATION HALF-LIFE; EXPERIMENTAL MONKEY; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IN VITRO STUDY; INSOMNIA; INTESTINAL DYSMOTILITY; ISOTOPE LABELING; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; PLASMA CONCENTRATION-TIME CURVE; RADIOACTIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAT; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; UNSPECIFIED SIDE EFFECT; VOLUME OF DISTRIBUTION AT STEADY-STATE; ANIMAL; BILE; BIOTRANSFORMATION; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; HAPLORHINI; LIVER MICROSOME; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; URINE;

ADMINISTRATION, ORAL; ADULT; ANIMALS; BILE; BIOTRANSFORMATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCURONIC ACID; GLUCURONOSYLTRANSFERASE; HAPLORHINI; HIV INTEGRASE INHIBITORS; HUMANS; MALE; MICE; MICROSOMES, LIVER; MIDDLE AGED; PYRIDONES; RATS;

EID: 84955658272     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2015.1060372     Document Type: Article

References (23)

1. Anderson MS, Kakuda TN, Hanley W, et al. (2008). Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother 52:4228-32.
2. Andrews CD, Spreen WR, Mohri H, et al. (2014). Long-acting integrase inhibitor protects macaques from interrectal simian/human immunodeficiency virus. Science 343:1151-14.
3. Castellino S, Moss L, Wagner D, et al. (2013). Metabolism, excretion and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob Agents Chemother 57:3536-46.
4. Chmela Z, Vesely J, Lemr K, et al. (2001). In vivo metabolism of 2,6,9-trisubstituted purine-derived cyclin-dependent kinase inhibitor bohemine in mice: glucosidation as the principal metabolic route. Drug Metab Dispos 29:326-34.
5. Curie L. (1968). Limits for qualitative detection and quantitative determination-application to radioactivity. Anal Chem 40:586-93.
6. European Medicines Agency. (2012). Guideline on the investigation of drug interactions. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/07/WC500129606.pdf [last accessed 5 May 2015].
7. Ford SL, Gould E, Chen S, et al. (2013). Effects of etravirine on the pharmacokinetics of the integrase inhibitor S/GSK1265744. Antimicrob Agents Chemother 57:277-80.
8. Gautam N, Roy U, Balkundi S, et al. (2013). Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy. Antimicrob Agents Chemother 57:3110-20.
9. Gill KL, Houston JB, Galetin A. (2012). Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. Drug Metab Dispos 40:825-35.
10. Guiney WJ, Beaumont C, Thomas SR, et al. (2011). Use of Entero-Test, a simple approach for non-invasive clinical evaluation of the biliary disposition of drugs. Br J Clin Pharmacol 72:133-42.
11. Hop CECA, Wang Z, Qing C, Kwei G. (1998). Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87:901-3.
12. Jackson AGA, Else JJ, Mesquita PMM, et al. (2014). A compartmental pharmacokietic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis. Clin Pharmacol Ther 96: 314-23.
13. Kassahun K, McIntosh I, Cui D, et al. (2007). Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 35:1657-63.
14. Loevinger RL, Budinger TF, Watson EE. (1991). MIRD primer for absorbed dose calculations. Revised ed. New York (NY): Society of Nuclear Medicine.
15. Moss L, Wagner D, Kanaoka E, et al. (2015). The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys. Xenobiotica 45: 60-70.
16. Reese MJ, Savina PM, Generaux GT, et al. (2013). In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos 41:353-61.
17. Roffey SJ, Obach RS, Gedge JI, Smith DA. (2007). What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 39:17-43.
18. Shipkova M, Strassburg CP, Braun F, et al. (2001). Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol 132: 1027-34
19. Song I, Borland J, Min S, et al. (2011). Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. Antimicrob Agents Chemother 55:3517-21.
20. Spreen W, Min S, Ford SL, et al. (2013a). Pharmacokinetics, safety and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials 14: 192-203.
21. Spreen WR, Margolis DA, Pottage JC. (2013b). Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS 8:565-71.
22. Spreen W, Ford SL, Chen S, et al. (2014). GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting (LA) injectable administration in healthy subjects. J Acquir Immune Defic Syndr 67: 481-6.
23. Tang B-K. (1990). Drug glucosidation. Pharmacol Ther 46:53-6.